Advertisement
Advertisement
Vyndamax

Vyndamax

tafamidis

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma

Marketer:

Pfizer
Concise Prescribing Info
Contents
Tafamidis
Indications/Uses
Wild-type or hereditary transthyretin amyloidosis in adults w/ cardiomyopathy.
Dosage/Direction for Use
Administration
May be taken with or without food: Swallow whole, do not crush/cut.
Contraindications
Special Precautions
Discontinue use in patients who undergo organ transplantation. Patients w/ NYHA Class IV. Increased LFTs & decreased thyroxine. Monitor patients & assess need for other therapy, including organ transplantation. Contains ≤44 mg sorbitol in each cap. Concomitant use w/ or dietary intake of products containing sorbitol (or fructose). Severe renal (CrCl ≤30 mL/min) & hepatic impairment. Women of childbearing potential should use appropriate contraception during & for 1 mth after stopping treatment. Not recommended during pregnancy & in women of childbearing potential not using contraception. Not to be used during lactation.
Adverse Reactions
Flatulence, increased LFT. Diarrhoea; rash, pruritus.
Drug Interactions
Inhibition of efflux transporter BCRP & increased systemic exposure of BCRP substrates eg, MTX, rosuvastatin, imatinib. Decreased serum conc of total thyroxine w/o accompanying change in free thyroxine (T4) or TSH.
MIMS Class
Other Cardiovascular Drugs
ATC Classification
N07XX08 - tafamidis ; Belongs to the class of other nervous system drugs.
Presentation/Packing
Form
Vyndamax soft-gelatin cap 61 mg
Packing/Price
3 × 10's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement